Marshall Wace, LLP Actinium Pharmaceuticals, Inc. Transaction History
Marshall Wace, LLP
- $72.2 Billion
- Q2 2024
A detailed history of Marshall Wace, LLP transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 256,026 shares of ATNM stock, worth $455,726. This represents 0.0% of its overall portfolio holdings.
Number of Shares
256,026
Previous 152,469
67.92%
Holding current value
$455,726
Previous $1.19 Million
58.76%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ATNM
# of Institutions
77Shares Held
7.11MCall Options Held
96.6KPut Options Held
70.5K-
Black Rock Inc. New York, NY1.88MShares$3.34 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.48MShares$2.63 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA666KShares$1.19 Million0.0% of portfolio
-
State Street Corp Boston, MA610KShares$1.09 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL228KShares$406,6570.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $44.8M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...